A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
Phase 1
Completed
- Conditions
- 3rd Line GIST
- Interventions
- Drug: ST571 + BYL719
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT01735968
- Locations
- 🇺🇸
Oregon Health and Science University Dept. of OHSU (3), Portland, Oregon, United States
🇬🇧Novartis Investigative Site, Leeds, United Kingdom
Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease
Phase 2
Terminated
- Conditions
- Peripheral Artery Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT01731990
- Locations
- 🇯🇴
Novartis Investigative Site, Amman, Jordan
A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 63
- Registration Number
- NCT01730248
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 147
- Registration Number
- NCT01730768
- Locations
- 🇺🇸
Novartis Investigative Site, Irving, Texas, United States
Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2012-11-15
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT01727024
- Locations
- 🇧🇷
Novartis Investigative Site, São Paulo, SP, Brazil
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2012-11-15
- Last Posted Date
- 2016-03-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1042
- Registration Number
- NCT01727141
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment
- First Posted Date
- 2012-11-15
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT01727128
- Locations
- 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation
An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old
- First Posted Date
- 2012-11-09
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01724138
Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
Phase 3
Completed
- Conditions
- Chronic Spontaneous UrticariaAngioedema
- Interventions
- Drug: PlaceboBiological: Omalizumab
- First Posted Date
- 2012-11-07
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 91
- Registration Number
- NCT01723072
- Locations
- 🇩🇪
Novartis Investigative Site, Wiesbaden, Germany
Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 471
- Registration Number
- NCT01716754
- Locations
- 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom